Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.03.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Kenichi Ogiwara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Japan. Electronic address: ogiwarak@naramed-u.ac.jp. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Factor VIIa, Blood Coagulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co Ltd.
Abstract (Originalsprache)
BACKGROUND: Concomitant administration of activated prothrombin complex concentrate (APCC) at doses >100 U/kg/d is associated with thrombotic risk under emicizumab prophylaxis. In vitro global assay data on the effects of concomitant coagulation factor agents in the presence of NXT007, an emicizumab-based engineered bispecific antibody under clinical development, may serve as a basis for addressing this potential risk. OBJECTIVES: This study aimed to investigate the in vitro effects of recombinant factor (rF)VIII, rFVIIa, and APCC during NXT007 treatment and estimate tolerable doses with reference to emicizumab. METHODS: Thrombin generation assays, clot waveform analysis, and rotational thromboelastometry were performed using hemophilia A plasma and blood samples spiked with NXT007 and others. RESULTS: A single dose of NXT007 at ≥10.0 μg/mL (plasma) achieved a nonhemophiliac coagulation potential. The concomitant addition of rFVIII, rFVIIa, and APCC each boosted various parameters following NXT007 levels at 0.1 to 50.0 μg/mL. In the copresence of NXT007 at 15.0 μg/mL (blood) and APCC at 0.13 U/mL, with the blood level immediately following the administration of 10.0 U/kg, the rotational thromboelastometry parameters were comparable with those observed with clinical emicizumab level and APCC at 0.63 U/mL, corresponding to the blood level immediately after administrating 50.0 U/kg (recommended initial dose). CONCLUSION: Concomitant addition of coagulation agents increased coagulation potentials in vitro in the presence of NXT007. A dose of 10.0 U/kg may serve as a rough indicator for the initial dose when exploring the concomitant use of APCC at plasma NXT007 levels of ∼30.0 μg/mL. Importantly, plasma NXT007 at ≥10.0 μg/mL demonstrated non-hemophiliac coagulation potentials in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nara Medical University, Kashihara, Japan. Electronic address: ogiwarak@naramed-u.ac.jp.
- Department of Pediatrics, Nara Medical University, Kashihara, Japan.
- Research Division, Chugai Pharmaceutical, Yokohama, Japan.
- Department of Pediatrics, Nara Medical University, Kashihara, Japan; The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Japan.
Förderung
- Chugai Pharmaceutical Co Ltd
Zitieren
APA
Ogiwara, K., Furukawa, S., Inaba, K., Sasai, K., Nakajima, Y., Shimonishi, N., Kitazawa, T., & Nogami, K. (2025). Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.03.034
Vancouver
Ogiwara K, Furukawa S, Inaba K, Sasai K, Nakajima Y, Shimonishi N, et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.03.034
BibTeX
@article{Ogiwara2025,
author = {Ogiwara, Kenichi and Furukawa, Shoko and Inaba, Keito and Sasai, Kana and Nakajima, Yuto and Shimonishi, Naruto and Kitazawa, Takehisa and Nogami, Keiji},
title = {Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.03.034}
}
EUVIMED